What Is SLOS Syndrome (Smith-Lemli-Opitz Syndrome)?

Smith-Lemli-Opitz syndrome (SLOS) is a genetic disorder in which the body cannot properly make cholesterol, leading to a shortage of cholesterol and a buildup of toxic precursor molecules that together cause a wide range of birth defects, intellectual disability, and behavioral problems. It is caused by mutations in a single gene called DHCR7, inherited in an autosomal recessive pattern, meaning a child must receive a faulty copy from each parent. First described in 1964, SLOS was the first recognized human syndrome tied to a defect in cholesterol production, and it remains one of the more common inborn errors of metabolism in people of European descent.

Why Cholesterol Matters More Than You Might Think

Cholesterol has a bad reputation in everyday health conversations, but it is actually essential for building cell membranes, producing certain hormones, and enabling critical signaling pathways during fetal development. The body manufactures most of its own cholesterol through a multi-step process. The very last step in that process is carried out by an enzyme called 7-dehydrocholesterol reductase, encoded by the DHCR7 gene. In people with SLOS, mutations in DHCR7 leave this enzyme partially or completely non-functional.¹

The consequences are twofold. First, the body cannot finish making cholesterol, so cholesterol levels drop. Second, the immediate precursor that was supposed to be converted into cholesterol, a molecule called 7-dehydrocholesterol (7-DHC), accumulates to abnormally high levels. For a long time, researchers assumed cholesterol deficiency was the main driver of SLOS symptoms. More recent work has shown the picture is more complex: the accumulated 7-DHC breaks down into highly reactive oxysterol byproducts that are directly toxic to cells, disrupt cell membranes, and interfere with receptor signaling.² So the disease is really a double hit: too little of something the body needs and too much of something that actively causes harm.

How Cholesterol Deficiency Disrupts Fetal Development

Many of the most serious problems in SLOS arise before birth. Cholesterol plays a direct role in the Sonic Hedgehog signaling pathway, one of the master regulatory systems that tells a developing embryo how to form its brain, face, limbs, and organs. The Sonic Hedgehog protein actually requires a cholesterol molecule to be physically attached to it in order to function properly. When cholesterol is scarce, this signaling goes awry, and the result can be structural malformations ranging from subtle to devastating.³

One of the most severe manifestations is holoprosencephaly, a condition in which the brain fails to divide properly into two hemispheres. Not every child with SLOS develops this, but the connection between cholesterol metabolism and Sonic Hedgehog signaling helps explain why the syndrome can affect so many different organ systems at once. Malformations of the face, heart, kidneys, genitals, and limbs all trace back to developmental pathways that depend on adequate cholesterol during narrow windows of embryonic growth.

Some maternal cholesterol does cross the placenta to the developing fetus, which can partially compensate for the fetus’s own inability to produce enough.⁴ This maternal supply may explain part of the wide variability in severity seen among affected children. Research in mouse models has shown that boosting placental cholesterol transport through a specific transporter protein called ABCA1 can increase the amount of cholesterol reaching an SLOS-affected fetus, offering a potential route for in utero treatment someday.⁵

The Clinical Spectrum

SLOS does not look the same in every affected person. The syndrome spans a wide continuum, from mild cases with subtle facial features and moderate learning difficulties to severe cases with life-threatening organ malformations and profound disability.⁶ Older medical literature sometimes split these into “type I” (milder) and “type II” (severe), but clinical studies have found no clean boundary between the two. The type I/II distinction has largely been abandoned in favor of viewing SLOS as a single condition with a continuous range of severity.⁷

Common physical features include:

Facial: small head (microcephaly), drooping eyelids, a short upturned nose, and a small jaw
Limbs: syndactyly of the second and third toes (a characteristic “Y-shaped” fusion), short thumbs, and sometimes extra fingers
Genital: ambiguous or underdeveloped genitalia in males, which can make sex assignment difficult at birth
Internal organs: heart defects, kidney malformations, and cleft palate in more severe cases
Skin: photosensitivity, meaning the skin reacts abnormally to sunlight

The severity of these features tracks roughly with the degree of residual enzyme activity. Children who retain some DHCR7 function tend to have milder physical features, while those with near-zero enzyme activity are more likely to have multiple organ malformations.⁸

Neurodevelopmental and Behavioral Effects

Intellectual disability is present in the majority of people with SLOS, though the degree varies widely. In one detailed study of 33 individuals, average cognitive scores fell in the moderate impairment range, but the full spectrum was represented, from profound disability to a single participant with scores in the average range.⁹ Adaptive behavior scores, which measure day-to-day functioning, were impaired across the board in that same cohort.

Autism spectrum disorder (ASD) is strikingly common. In the same study, about 55% of participants received a clinical ASD diagnosis, and roughly 60% exceeded the threshold on standardized autism assessments.⁹ This makes SLOS one of the genetic conditions most strongly associated with autism. Beyond ASD, behavioral features commonly include repetitive self-injury, extreme sensitivity to sensory stimuli like light and sound, hyperactivity, difficulty regulating emotions, and significant sleep disturbances.¹⁰

Language and motor development are usually delayed, sometimes substantially. Many children with SLOS do not walk or speak on the expected timeline, and some never achieve independent speech. These developmental challenges are among the hardest to address because they partly stem from structural brain differences laid down during fetal development, before any treatment can begin.

How Common Is SLOS

SLOS is most frequently seen in populations of European descent. Carrier frequency is highest among Ashkenazi Jews (roughly 1 in 43) and Northern Europeans (roughly 1 in 54).¹¹ One screening study of random newborn blood samples in the United States found that the overall carrier frequency for all DHCR7 mutations combined may be as high as about 1 in 30.¹²

That carrier frequency is surprisingly high for a condition that appears relatively rare in clinical practice. Based on carrier rates alone, you would expect roughly 1 in 1,600 to 1 in 13,500 births to be affected, yet the observed clinical incidence is much lower than even the conservative end of that range.¹² The gap is thought to result from high rates of in utero death: many severely affected embryos are lost to miscarriage early in pregnancy, before a diagnosis is ever made. Additionally, mildly affected individuals may go unrecognized if their only features are subtle toe syndactyly and learning difficulties. The condition is rare in populations of African and East Asian descent.

Diagnosis

SLOS is diagnosed by measuring the level of 7-DHC in the blood. In unaffected infants, 7-DHC is present at very low concentrations. In SLOS, levels can range from about 10 to more than 2,000 times the upper limit of normal, making the biochemical test highly reliable when the condition is suspected.¹³ Genetic testing of the DHCR7 gene confirms the diagnosis and identifies the specific mutations, which can provide some information about expected severity, though the correlation is imperfect.

Prenatal diagnosis is possible and is typically considered when there is a family history of SLOS, when ultrasound reveals suggestive findings like ambiguous genitalia or certain structural abnormalities, or when maternal blood tests show unusually low levels of unconjugated estriol (a pregnancy hormone that depends on fetal cholesterol metabolism for its production).¹⁴ Elevated 7-DHC can be detected in amniotic fluid or placental tissue. Standard newborn screening panels in most countries do not currently test for SLOS, which contributes to diagnostic delays in milder cases.

Cholesterol Supplementation

The most widely used treatment for SLOS is dietary cholesterol supplementation, typically given as egg yolk or a pharmaceutical cholesterol preparation. The rationale is straightforward: if the body cannot make enough cholesterol, supply it from outside. In an early study of six patients, cholesterol supplementation improved growth, accelerated developmental progress, reduced behavioral problems, improved tolerance of infections, and lessened photosensitivity, with no adverse effects reported.¹⁵ Another Scandinavian trial confirmed that photosensitivity improved in all treated patients and that progressive nerve damage showed some improvement as well.¹⁶

However, the evidence is not uniformly positive. A six-year longitudinal study found no measurable change in developmental level with cholesterol supplementation, and a fundamental biological barrier limits what dietary cholesterol can achieve: cholesterol does not easily cross the blood-brain barrier.¹⁷ The brain normally manufactures its own cholesterol supply, and in SLOS, that local production is impaired. Supplementing cholesterol through the diet can raise blood levels and benefit peripheral tissues, but it may not meaningfully reach the organ most in need. Furthermore, structural brain abnormalities formed during fetal development are irreversible regardless of later supplementation.

Despite these limitations, cholesterol supplementation remains the standard of care because it does appear to help with peripheral symptoms like growth, skin health, and gastrointestinal function. Most specialists view it as necessary but insufficient on its own.

Simvastatin and the Statin Debate

Adding a statin drug like simvastatin to cholesterol supplementation sounds counterintuitive, since statins are normally prescribed to lower cholesterol. But in SLOS, the goal of statin therapy is different: by partially blocking the cholesterol synthesis pathway upstream of the defective enzyme, statins reduce the production of 7-DHC, the toxic precursor that accumulates. In a placebo-controlled trial, simvastatin lowered the ratio of toxic precursors to total sterols in the blood of most treated participants.¹⁸ Crucially, unlike dietary cholesterol, simvastatin can cross the blood-brain barrier, and mouse studies showed it reduced 7-DHC in brain tissue as well as in peripheral organs.¹⁹

The combination of cholesterol supplementation with simvastatin led to an improved sterol ratio through different mechanisms: the supplemental cholesterol raised total cholesterol, while the simvastatin lowered the toxic 7-DHC fraction.²⁰ Still, statin therapy for SLOS remains somewhat controversial and is not universally adopted. A Cochrane review noted that evidence supporting statin use in SLOS consists mainly of anecdotal reports and preclinical studies rather than large randomized trials.²¹ Physicians remain cautious about giving a cholesterol-lowering drug to patients who are already cholesterol-deficient, even when the mechanistic rationale is sound.

Antioxidants as an Emerging Strategy

The recognition that toxic oxysterols derived from 7-DHC contribute to SLOS pathology opened a new therapeutic angle: antioxidants. If oxidative breakdown of 7-DHC generates harmful molecules, then blocking that oxidation could reduce damage. In laboratory experiments using skin cells from SLOS patients, exposure to a commercially available antioxidant mixture containing vitamins A, C, D, E, and coenzyme Q10 dramatically reduced levels of a key toxic oxysterol in a dose-dependent manner.²²

Early clinical results combining cholesterol supplementation with antioxidant vitamins have been described as extremely encouraging, though the evidence base is still small.² The appeal of antioxidants is that they address a different part of the disease mechanism than either cholesterol supplementation or statins, potentially complementing both. If validated in larger studies, a triple approach of supplemental cholesterol, statin therapy to reduce precursor buildup, and antioxidants to neutralize toxic byproducts could represent a more comprehensive treatment strategy.

Cholic Acid and Newer Observations

More recently, cholic acid, a bile acid that is itself made from cholesterol, has attracted interest. In a real-world series of patients treated with cholic acid, caregivers and healthcare professionals reported improvements in behavior, social interaction, cognitive engagement, and communication skills, along with better biochemical markers and quality of life.²³ These are observational findings rather than controlled trial data, and the mechanism by which cholic acid might benefit SLOS patients is not fully established. But bile acid metabolism is known to be disrupted in SLOS because bile acids are derived from cholesterol, so supplementing them directly is a logical extension of the overall treatment philosophy of replacing downstream products the body cannot make efficiently.

Gene Therapy Research

Because SLOS is caused by defects in a single gene, gene therapy is an attractive long-term goal. In mouse models of SLOS, researchers have used adeno-associated virus (AAV) vectors to deliver a working copy of the DHCR7 gene. Mice treated as newborns showed increased DHCR7 expression in the liver, improved cholesterol levels in the blood and liver, and faster weight gain compared to untreated animals.²⁴

Reaching the brain is the harder problem. To bypass the blood-brain barrier, one team injected the AAV vector directly into the cerebrospinal fluid of newborn mice. Two months later, treated animals showed improved sterol levels in both the brain and spinal cord, and the effect persisted into adulthood from a single neonatal dose.²⁵ These results are encouraging but strictly preclinical. No human gene therapy trials for SLOS have been conducted yet, and major questions remain about safety, durability, and whether biochemical improvement in the brain would translate to meaningful cognitive and behavioral benefits in people. Still, these animal studies provide proof of concept that the underlying sterol abnormality in the nervous system is at least partially correctable.

Other Disorders of Cholesterol Synthesis

SLOS was the first human syndrome linked to a defect in cholesterol production, but it is not the only one. Since the discovery of the DHCR7 connection in 1993, several other conditions involving enzymes in the same biosynthetic pathway have been identified. These include desmosterolosis, lathosterolosis, SC4MOL deficiency, and CK syndrome, among others.²⁶ Each of these conditions involves a different enzyme in the conversion of lanosterol to cholesterol, and they share overlapping but distinct patterns of malformations and developmental problems. Most are exceedingly rare, with only a handful of known cases worldwide.

Recognizing that these disorders exist matters for families going through a diagnostic workup. A child with features suggestive of SLOS but normal 7-DHC levels might have a different sterol synthesis defect. Specialized sterol profiling, which measures multiple intermediates in the cholesterol pathway rather than just 7-DHC, can help distinguish among these conditions. The expanding family of cholesterol biosynthesis disorders has also deepened researchers’ understanding of how cholesterol functions during development, providing insights that may eventually benefit treatment not just for SLOS but for this broader group of related conditions.

1
PubMed. Smith-Lemli-Opitz syndrome and the DHCR7 gene
2
PubMed Central. Antioxidants: The Missing Key to Improved Therapeutic Intervention in Smith-Lemli-Opitz Syndrome?
3
American Journal of Medical Genetics. Holoprosencephaly in RSH/Smith-Lemli-Opitz syndrome: Does abnormal cholesterol metabolism affect the function of sonic hedgehog?
4
PubMed Central. Review: Transport of maternal cholesterol to the fetal circulation
5
Human Molecular Genetics. Characterization of placental cholesterol transport: ABCA1 is a potential target for in utero therapy of Smith–Lemli–Opitz syndrome
6
The American Journal of Human Genetics. Mutational Spectrum in the Δ7-Sterol Reductase Gene and Genotype-Phenotype Correlation in 84 Patients with Smith-Lemli-Opitz Syndrome
7
Pediatric Research. Clinical Spectrum of Patients with RSH/Smith-Lemli-Opitz Syndrome
8
Genetics in Medicine. Smith-Lemli-Opitz syndrome: Clinical, biochemical, and genetic insights with emerging treatment opportunities
9
PubMed Central. Development, behavior, and biomarker characterization of Smith-Lemli-Opitz syndrome: an update
10
PubMed. Cognitive and behavioral aspects of Smith-Lemli-Opitz syndrome
11
PubMed Central. Smith–Lemli–Opitz syndrome carrier frequency and estimates of in utero mortality rates
12
PubMed. Carrier frequency of the common mutation IVS8-1G>C in DHCR7 and estimate of the expected incidence of Smith-Lemli-Opitz syndrome
13
PubMed. Diagnosis of Smith-Lemli-Opitz syndrome by gas chromatography/mass spectrometry of 7-dehydrocholesterol in plasma, amniotic fluid and cultured skin fibroblasts
14
StatPearls / Research Starter. Smith-Lemli-Opitz syndrome – Section: Screening and Diagnosis
15
American Journal of Medical Genetics. Clinical effects of cholesterol supplementation in six patients with the Smith-Lemli-Opitz syndrome (SLOS)
16
PubMed. Cholesterol treatment forever? The first Scandinavian trial of cholesterol supplementation in the cholesterol-synthesis defect Smith-Lemli-Opitz syndrome
17
PubMed Central. Use of a cholesterol emulsion in Smith-Lemli-Opitz syndrome (SLOS): A single-center observational study, retrospective analysis and structured caregiver interview
18
Genetics in Medicine. A placebo-controlled trial of simvastatin therapy in Smith-Lemli-Opitz syndrome
19
PubMed. Development and characterization of a hypomorphic Smith-Lemli-Opitz syndrome mouse model and efficacy of simvastatin therapy
20
PubMed. Effects of cholesterol and simvastatin treatment in patients with Smith-Lemli-Opitz syndrome (SLOS)
21
PubMed Central. Statins for Smith-Lemli-Opitz syndrome
22
PubMed Central. Antioxidant supplementation ameliorates molecular deficits in Smith-Lemli-Opitz Syndrome
23
PubMed Central. Use of cholic acid in Smith-Lemli-Opitz syndrome (SLOS): real-world patient outcomes
24
Molecular Genetics and Metabolism Reports. Biochemical and physiological improvement in a mouse model of Smith–Lemli–Opitz syndrome (SLOS) following gene transfer with AAV vectors
25
Molecular Genetics and Metabolism Reports. Delivery of the 7-dehydrocholesterol reductase gene to the central nervous system using adeno-associated virus vector in a mouse model of Smith-Lemli-Opitz Syndrome
26
PubMed Central. Disorders of sterol synthesis: beyond Smith-Lemli-Opitz syndrome